Back to the main directory
EarningsReview / Equity
- Svenska Handelsbanken (Buy, TP: SEK95.00) - Signalling Covid-19 resilience by DnB Markets
- Asarina Pharma (Hold, TP: SEK9.00) - Termination of PMDD development by DnB Markets
- Getinge (Hold, TP: SEK195.00) - Covid-19 driving 2020e earnings by DnB Markets
- Sparebank1 SR-Bank (Buy, TP: NOK75.00) - Higher loan-loss impairments by DnB Markets
- BioArctic (Buy, TP: SEK200.00) - No Covid-19 impact, as of yet by DnB Markets
- Tomra (Hold, TP: NOK350.00) - Does not look materially affected by DnB Markets
- HKBN (1310 HK) by HSBC
- Itaú BBA on Telesites: Positive 1Q20 – Resilient Business in Current Context by Itau
- Itaú BBA on IEnova: Good In-Line Results; Trading at 13.7% Implied IRR in USD by Itau
- Tele2 (TEL2B SS) by HSBC
- Itaú BBA on Genomma Lab: In-Line 1Q20 Results by Itau
- Atea - Still attractive, but ongoing issues in Denmark by Danske Bank Equity Research
- Bavarian Nordic - A vaccine cash cow by Danske Bank Equity Research
- Elisa - Sell/EUR 44 (43): Solid Q1 but COVID-19 and M&A headwinds ahead by Nordea
- Kone - Hold: Resilience already reflected in the valuation by Nordea
- Investor - Buy/SEK 578 (559): Solid Q1 delivery – discount still looks too high by Nordea
- Solid. Demand still strong but output constrained short term by BNP Paribas Exane
- New Wave Group - Hold: Question mark over whether 2020 will be profitable by Nordea
- Svenska Handelsbanken - Hold: Less dramatic than the market expected by Nordea
- Telia Company - Hold: COVID-19 uncertainty lingers over Telia by Nordea
- Q1 trading update - writing 2020 off... by BNP Paribas Exane
- At the moment, it''s all relative by BNP Paribas Exane
- Espresso | Covivio | Buy | Hotels suffering, the rest stays positive by Kepler Cheuvreux
- Cash flow resilience analysis by BNP Paribas Exane
- Investment Daily 23/04/2020 by BNP Paribas Exane